Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11501 - 11525 of 12867 in total
Experimental
Matched Iupac: … 2-[(3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amino]-1-(4 …
BMS-929075 is under investigation in clinical trial NCT01525212 (Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients).
Investigational
Matched Iupac: … 4-fluoro-2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-{[1-(pyrimidin-2-yl)cyclopropyl]carbamoyl}phenyl)- …
Investigational
Matched Iupac: … (4S)-4-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(2S)-6-amino-1-[(2S)-2-{[(1S,2R)-1-carboxy-2-hydroxypropyl ... ]carbamoyl}pyrrolidin-1-yl]-1-oxohexan-2-yl]carbamoyl}-3-methylbutyl]carbamoyl}-2-hydroxyethyl]carbamoyl ... }-2-methylpropyl]carbamoyl}ethyl]carbamoyl}-4-tetradecanamidobutanoic acid …
SCY-635 has been investigated for the treatment of Chronic Hepatitis C and Hepatitis C Infection.
Investigational
Matched Iupac: … 4E)-1-hydroxy-2-methylhex-4-en-1-yl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl ... -6,9,18-tris(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan ... (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-27-{[2-(dimethylamino)ethyl]sulfanyl}-30-ethyl-33-[(1R,2R, …
Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection. It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. Surotomycin has a fourfold greater in vitro potency than vancomycin against C. Difficile and other...
Investigational
Matched Iupac: … (3S)-3-{[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21 ... [(2S)-3-(1H-indol-3-yl)-2-[(2E)-3-(4-pentylphenyl)but-2-enamido]propanamido]propanamido]propanoic acid ... decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontan-30-yl]carbamoyl}-3-[(2R)-3-carbamoyl-2- ... -bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29 …
Experimental
Matched Iupac: … (1S)-1-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-5-amino-1-{[(1S)-1-{[(1S)-1-{[(1S)-2-carbamoyl-1-{[(1S)-1-{[( ... [(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-5-yl)propanamido]-3-hydroxypropanamido ... (3S)-3-{[(1S)-1-{[(1S)-1-{[(1S,2R)-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-1-{[(1S)-1-{[ ... hydroxybutyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}-2-carbamoylethyl]carbamoyl}-3-[(2S,3R)-2- ... 1S,2S)-1-{[(1S)-1-{[(1S)-2-carbamoyl-1-carboxyethyl]carbamoyl}-3-methylbutyl]carbamoyl}-2-methylbutyl …
Investigational
Matched Iupac: … (1S)-1-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-5-amino-1-{[(1S)-1-{[(1S)-1-{[(1S)-2-carbamoyl-1-{[(1S)-1-{[( ... (3S)-3-{[(1S)-1-{[(1S)-1-{[(1S,2R)-1-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-1-{[(1S)-1-{[ ... -[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-hydroxypropanamido ... hydroxypropyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}-2-carbamoylethyl]carbamoyl}-3-[(2S,3R)-2 ... 1S,2S)-1-{[(1S)-1-{[(1S)-2-carbamoyl-1-carboxyethyl]carbamoyl}-3-methylbutyl]carbamoyl}-2-methylbutyl …
Experimental
Matched Iupac: … 2-[(2R)-2-(4-aminobutanamido)-3-{[(4-methoxyphenyl)methyl]sulfanyl}propanamido]acetic acid …
Experimental
Matched Iupac: … (2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-sulfoethyl]carbamoyl}butanoic acid …
Experimental
Matched Iupac: … 4-[(2S)-2-azaniumyl-2-carboxyethyl]-5-tert-butyl-1,2-thiazol-3-olate …
CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.
Investigational
Matched Iupac: … (2S,3S)-N-{[2-methoxy-5-(trifluoromethoxy)phenyl]methyl}-2-phenylpiperidin-3-amine …
Investigational
Matched Iupac: … 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c]1,5-naphthyridin-4-amine …
Investigational
Matched Iupac: … 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole …
TO-901317 is an LXRalpha and LXRbeta agonist.
Experimental
Matched Iupac: … N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N-(2,2,2-trifluoroethyl)benzenesulfonamide …
GSI-136 has been used in trials studying the treatment of Alzheimer Disease.
Investigational
Matched Iupac: … 5-chloro-N-[(2S)-3-ethyl-1-hydroxypentan-2-yl]thiophene-2-sulfonamide …
Experimental
Matched Iupac: … 5,6-dimethoxy-2-methyl-3-[2-(4-phenylpiperazin-1-yl)ethyl]-1H-indole …
Investigational
Matched Iupac: … (2S)-3-(2-sulfanylidene-2,3-dihydro-1H-imidazol-4-yl)-2-(trimethylazaniumyl)propanoate …
Becocalcidiol is a vitamin D(3) analogue which has not caused hypercalcaemia or significant irritation in preclinical trials.
Investigational
Matched Iupac: … (1R,3R)-5-{2-[(1R,3aS,4E,7aR)-1-[(2S)-butan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}- ... 2-methylidenecyclohexane-1,3-diol …
Timcodar has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Iupac: … (2S)-N-benzyl-N-[1,5-bis(pyridin-4-yl)pentan-3-yl]-3-(4-chlorophenyl)-2-[N-methyl-2-oxo-2-(3,4,5-trimethoxyphenyl …
BMS-817399 is under investigation in clinical trial NCT01404585 (Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis).
Investigational
Matched Iupac: … (2-hydroxy-2-methylpropyl)urea ... 1-[(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl]-3- …
Leptazoline B is a polar oxazoline from the Cyanobacterium Leptolyngbya sp. Also see Leptazoline A, Leptazoline C, and Leptazoline D.
Experimental
Matched Iupac: … (2S,3S)-3-[(4S,5S)-2-(5-chloro-2-hydroxyphenyl)-5-methyl-4,5-dihydro-1,3-oxazol-4-yl]-N-(1,3-dihydroxypropan ... -2-yl)-2,3-dihydroxypropanamide …
UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria. Plasmepsins are aspartyl proteases produced by the malaria parasite Plasmodium falciparum, and PMX is considered to be essential for parasite egress and invasion. UCB7362 is estimated to achieve a significant reduction in asexual blood-stage...
Investigational
Matched Iupac: … N-{2-chloro-3-[(4S)-2-imino-4-methyl-1-[(2S,4S)-2-methyloxan-4-yl]-6-oxo-1,3-diazinan-4-yl]phenyl}-3- …
SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).
Investigational
Matched Iupac: … -1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]carbamoyl}-3-methylbutyl]carbamoyl}-2-phenylethyl]carbamoyl ... (4S)-4-{[(1S)-1-{[(1S)-1-{[(2S)-1-[(2S)-2-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-1-{[(1S)-1-{[(2S)-1-[(2S)- ... }-2-carboxyethyl]carbamoyl}-2-methylpropyl]carbamoyl}pentyl]carbamoyl}-2-hydroxyethyl]carbamoyl}pyrrolidin ... 2-{[(1S)-4-carbamimidamido-1-carboxybutyl]carbamoyl}pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]carbamoyl …
Onatasertib (CC-223) has been used in trials studying the treatment and basic science of Multiple Myeloma, Glioblastoma Multiforme, HepatoCellular Carcinoma, Non-small Cell Lung Cancer, and Diffuse Large B-Cell Lymphoma, among others.
Investigational
Matched Iupac: … 1,4]diazin-2-one ... 7-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(1r,4r)-4-methoxycyclohexyl]-1H,2H,3H,4H-pyrazino[2,3-b][ …
XL888 has been used in trials studying the treatment of Cancer and Melanoma.
Investigational
Matched Iupac: … 5-{[(2R)-butan-2-yl]amino}-N1-[(1R,3R,5S)-8-(5-cyclopropanecarbonylpyridin-2-yl)-8-azabicyclo[3.2.1]octan ... -3-yl]-2-methylbenzene-1,4-dicarboxamide …
Displaying drugs 11501 - 11525 of 12867 in total